Biotech Values

[rkrw]

The value does need to be discounted back to the present.

As far as CVR2, the one loophole that could put CSL back in the lead would be if they resubmit <4/3 and the fda gives them a class 1, 2 month review. A lot of people think the fda will game it in favor of csl to prevent a vphm monopoly.